Despite the discrepancy between CO and melanoma cells in response to NGLY1 loss, NGLY1-deficient CO cells, compared with the functional ones, showed higher susceptibility to either bortezomib, glutamate, hydrogen peroxide, or thapsigargin (Fig. 4A–D). This evidence concerns the gene NGLY1 and melanoma.